Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients: Reduced activity of cholesterol 7α-hydroxylase

Dagny Stahlberg, Eva Reihner, Mats Rudling, Lars Berglund, Kurt Einarsson, BO O. Angelin

Research output: Contribution to journalArticle

Abstract

Bezafibrate is a hypolipidemic fibric acid derivative known to induce cholesterol supersaturation of bile. To characterize its effects on hepatic cholesterol metabolism, 31 normolipidemic, normal-weight patients with gallstones undergoing cholecystectomy were studied. Eleven patients (5 men) were randomized to treatment with bezafibrate, 200 mg three times daily for 4 weeks before operation; the remaining 20 patients (5 men) served as nontreatment controls. At operation, a liver biopsy specimen was obtained under standardized conditions and several important parameters of cholesterol metabolism were assayed. Bezafibrate treatment lowered total plasma cholesterol and triglycerides 30% and 37%, respectively. The hepatic cholesterol 7a-hydroxylase activity was reduced by ≈60% in the bezafibrate treated patients compared with the controls, whereas the acyl-coenzyme A: cholesterol acyltransferase (ACAT) activity was similar in the two groups. The total 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase activity was increased twofold in the treated patients, whereas the active enzyme remained about the same as in the controls. The low-density lipoprotein (LDL) receptor binding activity was unaffected by the treatment. Bezafibrate treatment significantly reduces cholesterol 7a-hydroxylase activity, and it is suggested that this may play an important role for the development of supersaturated bile during such therapy.

Original languageEnglish (US)
Pages (from-to)1025-1030
Number of pages6
JournalHepatology
Volume21
Issue number4
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Bezafibrate
Cholesterol 7-alpha-Hydroxylase
Gallstones
Cholesterol
Liver
Mixed Function Oxygenases
Bile
Sterol O-Acyltransferase
Fibric Acids
Therapeutics
Acyl Coenzyme A
LDL Receptors
Cholecystectomy
Oxidoreductases
Triglycerides
Biopsy
Weights and Measures
Enzymes

ASJC Scopus subject areas

  • Hepatology

Cite this

Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients : Reduced activity of cholesterol 7α-hydroxylase. / Stahlberg, Dagny; Reihner, Eva; Rudling, Mats; Berglund, Lars; Einarsson, Kurt; Angelin, BO O.

In: Hepatology, Vol. 21, No. 4, 1995, p. 1025-1030.

Research output: Contribution to journalArticle

Stahlberg, Dagny ; Reihner, Eva ; Rudling, Mats ; Berglund, Lars ; Einarsson, Kurt ; Angelin, BO O. / Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients : Reduced activity of cholesterol 7α-hydroxylase. In: Hepatology. 1995 ; Vol. 21, No. 4. pp. 1025-1030.
@article{4f809fc956d34887a344e54b95a9dd37,
title = "Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients: Reduced activity of cholesterol 7α-hydroxylase",
abstract = "Bezafibrate is a hypolipidemic fibric acid derivative known to induce cholesterol supersaturation of bile. To characterize its effects on hepatic cholesterol metabolism, 31 normolipidemic, normal-weight patients with gallstones undergoing cholecystectomy were studied. Eleven patients (5 men) were randomized to treatment with bezafibrate, 200 mg three times daily for 4 weeks before operation; the remaining 20 patients (5 men) served as nontreatment controls. At operation, a liver biopsy specimen was obtained under standardized conditions and several important parameters of cholesterol metabolism were assayed. Bezafibrate treatment lowered total plasma cholesterol and triglycerides 30{\%} and 37{\%}, respectively. The hepatic cholesterol 7a-hydroxylase activity was reduced by ≈60{\%} in the bezafibrate treated patients compared with the controls, whereas the acyl-coenzyme A: cholesterol acyltransferase (ACAT) activity was similar in the two groups. The total 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase activity was increased twofold in the treated patients, whereas the active enzyme remained about the same as in the controls. The low-density lipoprotein (LDL) receptor binding activity was unaffected by the treatment. Bezafibrate treatment significantly reduces cholesterol 7a-hydroxylase activity, and it is suggested that this may play an important role for the development of supersaturated bile during such therapy.",
author = "Dagny Stahlberg and Eva Reihner and Mats Rudling and Lars Berglund and Kurt Einarsson and Angelin, {BO O.}",
year = "1995",
doi = "10.1016/0270-9139(95)90250-3",
language = "English (US)",
volume = "21",
pages = "1025--1030",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients

T2 - Reduced activity of cholesterol 7α-hydroxylase

AU - Stahlberg, Dagny

AU - Reihner, Eva

AU - Rudling, Mats

AU - Berglund, Lars

AU - Einarsson, Kurt

AU - Angelin, BO O.

PY - 1995

Y1 - 1995

N2 - Bezafibrate is a hypolipidemic fibric acid derivative known to induce cholesterol supersaturation of bile. To characterize its effects on hepatic cholesterol metabolism, 31 normolipidemic, normal-weight patients with gallstones undergoing cholecystectomy were studied. Eleven patients (5 men) were randomized to treatment with bezafibrate, 200 mg three times daily for 4 weeks before operation; the remaining 20 patients (5 men) served as nontreatment controls. At operation, a liver biopsy specimen was obtained under standardized conditions and several important parameters of cholesterol metabolism were assayed. Bezafibrate treatment lowered total plasma cholesterol and triglycerides 30% and 37%, respectively. The hepatic cholesterol 7a-hydroxylase activity was reduced by ≈60% in the bezafibrate treated patients compared with the controls, whereas the acyl-coenzyme A: cholesterol acyltransferase (ACAT) activity was similar in the two groups. The total 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase activity was increased twofold in the treated patients, whereas the active enzyme remained about the same as in the controls. The low-density lipoprotein (LDL) receptor binding activity was unaffected by the treatment. Bezafibrate treatment significantly reduces cholesterol 7a-hydroxylase activity, and it is suggested that this may play an important role for the development of supersaturated bile during such therapy.

AB - Bezafibrate is a hypolipidemic fibric acid derivative known to induce cholesterol supersaturation of bile. To characterize its effects on hepatic cholesterol metabolism, 31 normolipidemic, normal-weight patients with gallstones undergoing cholecystectomy were studied. Eleven patients (5 men) were randomized to treatment with bezafibrate, 200 mg three times daily for 4 weeks before operation; the remaining 20 patients (5 men) served as nontreatment controls. At operation, a liver biopsy specimen was obtained under standardized conditions and several important parameters of cholesterol metabolism were assayed. Bezafibrate treatment lowered total plasma cholesterol and triglycerides 30% and 37%, respectively. The hepatic cholesterol 7a-hydroxylase activity was reduced by ≈60% in the bezafibrate treated patients compared with the controls, whereas the acyl-coenzyme A: cholesterol acyltransferase (ACAT) activity was similar in the two groups. The total 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase activity was increased twofold in the treated patients, whereas the active enzyme remained about the same as in the controls. The low-density lipoprotein (LDL) receptor binding activity was unaffected by the treatment. Bezafibrate treatment significantly reduces cholesterol 7a-hydroxylase activity, and it is suggested that this may play an important role for the development of supersaturated bile during such therapy.

UR - http://www.scopus.com/inward/record.url?scp=0028931304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028931304&partnerID=8YFLogxK

U2 - 10.1016/0270-9139(95)90250-3

DO - 10.1016/0270-9139(95)90250-3

M3 - Article

C2 - 7705775

VL - 21

SP - 1025

EP - 1030

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 4

ER -